IP Library Granted Patent US 8,128,924
Granted Patent B2
US 8,128,924 · App. 12/420,716 · Granted Mar 6, 2012

Methods for using a three-dimensional stromal tissue to promote angiogenesis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,128,924
App. No.
12/420,716
Granted
Mar 6, 2012
Kind
B2
Abstract

The present invention relates to a method for promoting blood vessel formation in tissues and organs. In particular, the method relates to implantation or attachment of an engineered three-dimensional stromal tissue to promote endothelialization and angiogenesis in the heart and related tissues. The three-dimensional stromal tissue of the present invention may be used in a variety of applications including, but not limited to, promoting repair of and regeneration of damaged cardiac muscle, promoting vascularization and healing during cardiac surgery, promoting blood vessel formation at anastomosis sites, and promoting vascularization and repair of damaged skeletal muscle, smooth muscle or connective tissue.

Claims (20)

1. A method for effecting angiogenesis in ischemic heart tissue of a subject, comprising:

contacting ischemic heart tissue of said subject with a three-dimensional stromal tissue,

wherein said three-dimensional stromal tissue comprises fibroblasts and connective tissue proteins naturally secreted by the fibroblasts, said fibroblasts being attached to and substantially enveloping a framework composed of a biocompatible, non-living material formed into a three-dimensional structure having interstitial spaces bridged by the fibroblasts;

wherein fibroblasts are the sole cell type present in the three-dimensional stromal tissue, and

wherein said stromal tissue is capable of effecting angiogenesis in ischemic heart tissue.

2. The method of claim 1 wherein the framework is composed of a biodegradable material.

3. The method of claim 2 wherein the biodegradable material is polyglycolic acid, catgut sutures, cellulose, gelatin, collagen, or dextran.

4. The method of claim 1 wherein the framework is a mesh.

5. The method of claim 1 wherein the stromal tissue is obtained directly from a fresh culture.

6. The method of claim 1 wherein the stromal tissue has been cryopreserved.

7. The method of claim 1 further comprising adhering the stromal tissue to the ischemic heart tissue by natural cellular attachment.

8. The method of claim 1 further comprising attaching the stromal tissue to the ischemic heart tissue by means of a biodegradable or non-biodegradable suture, a biologic glue, a synthetic glue, a laser dye, or a hydrogel.

9. The method of claim 1 wherein the ischemic tissue is of the heart epicardium.

10. A method for effecting vascularization in damaged cardiac tissue of a subject, comprising

attaching a three-dimensional stromal tissue to an epicardial or myocardial surface near a damaged region of cardiac tissue of a subject,

wherein the three-dimensional stromal tissue comprises fibroblasts and connective tissue proteins naturally secreted by the fibroblasts, said fibroblasts being attached to and substantially enveloping a framework composed of a biocompatible, non-living material formed into a three-dimensional structure having interstitial spaces bridged by the fibroblasts;

wherein fibroblasts are the sole cell type present in the three-dimensional stromal tissue, and

wherein said stromal tissue is capable of effecting vascularization in damaged cardiac tissue.

11. The method of claim 10 , wherein the damaged region is ischemic.

12. The method of claim 10 , wherein said attaching comprises attaching the stromal tissue to the damaged region by means of a biodegradable or non-biodegradable suture, a biologic glue, a synthetic glue, a laser dye, or a hydrogel.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Aug 12, 2026
From: FIRST-CITIZENS BANK & TRUST COMPANY
To: ORGANOGENESIS HOLDINGS, INC.; ORGANOGENESIS, INC.; PRIME MERGER SUB, LLC
Reel/Frame 075619/0625 →
TERMINATION AND RELEASE OF PATENT SECURITY AGREEMENT Recorded Aug 6, 2021
From: ORGANOGENESIS INC.
To: SILICON VALLEY BANK
Reel/Frame 057112/0677 →
SECURITY INTEREST Recorded Mar 14, 2019
From: ORGANOGENESIS HOLDINGS INC.; ORGANOGENESIS, INC.; PRIME MERGER SUB, LLC
To: SILICON VALLEY BANK
Reel/Frame 048599/0130 →
SECURITY INTEREST Recorded Jun 19, 2018
From: ORGANOGENESIS INC.
To: SILICON VALLEY BANK
Reel/Frame 046392/0242 →
SECURITY INTEREST Recorded Mar 21, 2017
From: ORGANOGENESIS INC.
To: SILICON VALLEY BANK
Reel/Frame 041667/0558 →
MERGER Recorded Jan 25, 2012
From: THEREGEN, INC., A CALIFORNIA CORPORATION
To: THEREGEN, INC., A DELAWARE CORPORATION
Reel/Frame 027590/0948 →
CHANGE OF NAME Recorded Jan 23, 2012
From: IKEN TISSUE THERAPEUTICS
To: THEREGEN, INC.
Reel/Frame 027578/0706 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2012
From: ATS LIQUIDATING TRUST
To: IKEN TISSUE THERAPEUTICS
Reel/Frame 027563/0124 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2012
From: NAUGHTON, GAIL K.; MANSBRIDGE, JONATHAN N.; PINNEY, ROBERT E.; ZELTINGER, JOAN
To: ADVANCED TISSUE SCIENCES, INC.
Reel/Frame 027545/0811 →